Diabetic foot infection: Difference between revisions

From IDWiki
Content deleted Content added
WIfI System: moved to own page
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Background==
==Background==

* Foot infection in a patient with [[diabetes mellitus]], typically superimposed infection of a preexisting [[diabetic foot ulcer]]


===Microbiology===
===Microbiology===
Line 6: Line 8:
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections
**[[Coagulase-negative staphylococci]]
**[[Coagulase-negative staphylococci]]
**[[Streptococcus species]]
**[[Streptococcus]]
**[[Enterococcus species]]
**[[Enterococcus]]
**[[Enterobacteriaceae]]
**[[Enterobacteriaceae]]
**[[Pseudomonas aeruginosa]]
**[[Pseudomonas aeruginosa]]
**[[Anaerobes]], including [[Bacteroides fragilis]]
**[[Anaerobes]], including [[Bacteroides fragilis]]
*Anaerobes are more likely to be involved in deeper, more chronic ulcers
*Anaerobes are more likely to be involved in deeper, more chronic ulcers

== Classification ==

=== IDSA/IWGDF ===
{| class="wikitable"
!Clinical Manifestation
!Severity
!PEDIS Grade
|-
|Wound lacking purulence or any manifestations of inflammation
|Uninfected
|1
|-
|Presence of ≥ 2 manifestations of inflammation (purulence, or erythema, tenderness, warmth, or induration), but any cellulitis/erythema extends ≤ 2cm around the ulcer, and infection is limited to the skin or superficial subcutaneous tissues; no other local complications or systemic illness
|Mild
|2
|-
|Infection (as above) in a patient who is systemically well and metabolically stable but which has ≥ 1 of the following characteristics: cellulitis extending >2cm, lymphangitic streaking, spread beneath the superficial fascia, deep-tissue abscess, gangrene, and involvement of muscle, tendon, joint or bone
|Moderate
|3
|-
|Infection in a patient with systemic toxicity or metabolic instability (e.g. fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, or azotaemia)
|Severe
|4
|}

=== WIfI System ===

* The [[WIfI system]] is used to stage at-risk limbs in patients with peripheral artery disease, including those with diabetes
* Components include Wound, Ischemia, and foot Infection
* Clinical stage from 0 (very low) to 3 (high) which predicts amputation risk


==Diagnosis==
==Diagnosis==
Line 29: Line 62:
|-
|-
| rowspan="7" |Mild
| rowspan="7" |Mild
| rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus species]]
| rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus]]
|[[dicloxacillin]]
|[[dicloxacillin]]
|qid dosing and very narrow-spectrum
|qid dosing and very narrow-spectrum
Line 53: Line 86:
|-
|-
| rowspan="13" |moderate or severe
| rowspan="13" |moderate or severe
| rowspan="9" |[[MSSA]], [[Streptococcus species]], [[Enterobacteriaceae]], [[anaerobes]]
| rowspan="9" |[[MSSA]], [[Streptococcus]], [[Enterobacteriaceae]], [[anaerobes]]
|[[levofloxacin]]
|[[levofloxacin]]
|suboptimal against MSSA
|suboptimal against MSSA

Latest revision as of 17:00, 18 September 2025

Background

Microbiology

Classification

IDSA/IWGDF

Clinical Manifestation Severity PEDIS Grade
Wound lacking purulence or any manifestations of inflammation Uninfected 1
Presence of ≥ 2 manifestations of inflammation (purulence, or erythema, tenderness, warmth, or induration), but any cellulitis/erythema extends ≤ 2cm around the ulcer, and infection is limited to the skin or superficial subcutaneous tissues; no other local complications or systemic illness Mild 2
Infection (as above) in a patient who is systemically well and metabolically stable but which has ≥ 1 of the following characteristics: cellulitis extending >2cm, lymphangitic streaking, spread beneath the superficial fascia, deep-tissue abscess, gangrene, and involvement of muscle, tendon, joint or bone Moderate 3
Infection in a patient with systemic toxicity or metabolic instability (e.g. fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, or azotaemia) Severe 4

WIfI System

  • The WIfI system is used to stage at-risk limbs in patients with peripheral artery disease, including those with diabetes
  • Components include Wound, Ischemia, and foot Infection
  • Clinical stage from 0 (very low) to 3 (high) which predicts amputation risk

Diagnosis

  • Osteomyelitis should be considered in all cases of diabetic foot infection
    • Probe-to-bone test should be done routinely
    • Plain film X-ray can be helpful, though not sensitive
    • MRI is the preferred diagnostic test, followed by bone and white cell scan
    • The gold standard is still bone biopsy for histopathology and culture

Management

Severity Common Pathogens Antibiotics Notes
Mild methicillin-susceptible Staphylococcus aureus, Streptococcus dicloxacillin qid dosing and very narrow-spectrum
clindamycin active against MRSA but higher risk of CDAD
cephalexin qid dosing
levofloxacin not as effective against Staphylococcus aureus
amoxicillin-clavulanic acid broad-spectrum, includes anaerobic coverage
methicillin-resistant Staphylococcus aureus doxycycline uncertain activity against streptococci
TMP-SMX uncertain activity against streptococci
moderate or severe MSSA, Streptococcus, Enterobacteriaceae, anaerobes levofloxacin suboptimal against MSSA
cefoxitin
ceftriaxone
ampicillin-sulbactam
moxifloxacin
ertapenem
tigecycline
fluoroquinolone with clindamycin
imipenem-cilastatin
MRSA linezolid
daptomycin
vancomycin
Pseudomonas aeruginosa piperacillin-tazobactam

Duration

Site of Infection Severity Duration
soft tissue only mild 1 to 2 weeks; up to 4 weeks if slow-to-resolve
moderate 1 to 3 weeks
severe 2 to 4 weeks
bone and joint infection postamputation, with no residual infection 2 to 5 days
postamputation, with residual soft tissue infection 1 to 3 weeks
postamputation, with residual bone infection 4 to 6 weeks
no surgery ≥3 months
  • Osteomyelitis
    • Traditionally, 6 weeks of parenteral therapy
    • May be able to shorten to 3 weeks if adequately debrided, based on more recent evidence1

Further Reading

References

  1. ^  Karim Gariani, Truong-Thanh Pham, Benjamin Kressmann, François R Jornayvaz, Giacomo Gastaldi, Dimitrios Stafylakis, Jacques Philippe, Benjamin A Lipsky, İlker Uçkay. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1758.